Carregant...
Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges
Primary liver cancer is one of the commonest causes of death. Hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancers. For patients with unresectable or metastatic HCC, conventional chemotherapy is of limited or no benefit. Sorafenib is the only systemic treatment to demonstrate a s...
Guardat en:
| Publicat a: | World J Hepatol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Baishideng Publishing Group Inc
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4404384/ https://ncbi.nlm.nih.gov/pubmed/25914779 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v7.i5.787 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|